Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Chan You, Seng; Rho, Yeunsook; Bikdeli, Behnood; Kim, Jiwoo; Siapos, Anastasios; Weaver, James; Londhe, Ajit; Cho, Jaehyeong; Park, Jimyung; J. Schuemie, Martijn; A. Suchard, Marc; Madigan, David; Hripcsak, George; Gupta, Aakriti; Reich, Christian; Ryan, Patrick; Woong Park, Rae; M. Krumholz, Harlan

doi:10.1001/jama.2020.16167

Public

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Published in JAMA • Oct 27, 2020

Authors:

Seng Chan You

Yeunsook Rho

Behnood Bikdeli

Abstract

Importance: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits atte...

Subject

Medicine

Ticagrelor

Clopidogrel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!